480 results on '"Hainsworth, J D"'
Search Results
2. Chronic Etoposide Schedules in the Treatment of Non-Hodgkin’s Lymphoma
3. Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset
4. Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study†
5. King Lear and John Brown's Athelstan
6. James Townley and The Clandestine Marriage
7. David Garrick's Address to the Audience on Behalf of the Drury Lane Theatrical Fund
8. Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT
9. Survival of patients with metastatic basal cell carcinoma and distant metastasis: the effect of vismodegib, a Hedgehog pathway inhibitor: P-267
10. Efficacy and safety of vismodegib in patients with advanced basal cell carcinoma (BCC): 12-month update of the ERIVANCE BCC study
11. Panel discussion on B cells and rituximab: mechanistic aspects, efficacy and safety in rheumatoid arthritis and non-Hodgkinʼs lymphoma
12. Introduction
13. The Date of David Garrick's Lines to George Lyttelton
14. Carcinoma of unknown primary site: Phase II trials with docetaxel plus cisplatin or carboplatin
15. Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome : final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study
16. Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma
17. Efficacy of Octreotide LAR (OCT) in Patients (pts) with Advanced Neuroendocrine Tumors (NET) : A Subgroup Analysis of Phase III RADIANT-2 Study with Updated Overall Survival (OS)
18. Everolimus plus octreotide long-acting release (LAR) for the treatment of advanced neuroendocrine tumors (NET) associated with carcinoid syndrome (RADIANT-2) : Updated overall survival results
19. Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset
20. Randomized phase II study of R-CHOP plus enzastaurin versus R-CHOP in the first-line treatment of patients with intermediate- and high-risk diffuse large B-cell lymphoma (DLBCL): Preliminary analysis.
21. Lenalidomide in combination with gemcitabine in patients with untreated metastatic carcinoma of the pancreas: A Sarah Cannon Research Institute phase II trial.
22. Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): Effect of prior somatostatin analog therapy on progression-free survival in the RADIANT-2 trial.
23. High-dose bevacizumab in the treatment of patients with advanced clear cell renal carcinoma (RCC): A Sarah Cannon Research Institute phase II trial.
24. Carcinoma of unknown primary site (CUP): Outcomes in patients with a colorectal molecular profile treated with site-specific chemotherapy.
25. Molecular tumor profiling (MTP) in cancer of unknown primary site (CUP): A complement to standard pathologic diagnosis.
26. Randomized phase III trial of gemcitabine/carboplatin with or without iniparib (BSI-201) in patients with previously untreated stage IV squamous non-small cell lung cancer (NSCLC).
27. Ixabepilone and cyclophosphamide as neoadjuvant therapy in HER2-negative breast cancer with exploratory Oncotype DX assessments: A Sarah Cannon Research Institute phase II trial.
28. Safety, efficacy, and pharmacodynamics of the investigational agent TAK-700 in metastatic castration-resistant prostate cancer (mCRPC): Updated data from a phase I/II study.
29. Phase II study of NK012 in relapsed small cell lung cancer.
30. Pazopanib in patients with metastatic renal cell carcinoma previously treated with sunitinib or bevacizumab: A Sarah Cannon Research Institute phase II trial.
31. Neoadjuvant ixabepilone/carboplatin/trastuzumab in HER2-positive locally advanced breast cancer: A Sarah Cannon Research Institute phase II trial.
32. Amrubicin as second- or third-line treatment for patients with HER2-negative metastatic breast cancer (MBC): A Sarah Cannon Research Institute phase I trial.
33. Sorafenib and everolimus (RAD001) in the treatment of patients with advanced clear cell renal carcinoma (RCC): A Sarah Cannon Research Institute phase I/II trial.
34. TITAN: Ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple-negative breast cancer (TNBC): Preliminary toxicity of a Sarah Cannon Research Institute phase III trial.
35. Everolimus plus octreotide LAR (E+O) versus placebo plus octreotide LAR (P+O) in patients with advanced neuroendocrine tumors (NET): Updated results of a randomized, double-blind, placebo-controlled, multicenter phase III trial (RADIANT-2).
36. A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer.
37. A randomized phase II study of paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer.
38. Use of maintenance rituximab (R) in the United States following R-based induction for follicular lymphoma (FL).
39. Trial of poor performance status patients (ToPPS): A randomized phase II trial of pemetrexed versus pemetrexed/bevacizumab versus pemetrexed/carboplatin/bevacizumab in patients with stage IIIb/IV non-small cell lung cancer and ECOG performance status 2.
40. Phase II study of irinotecan and carboplatin followed by maintenance sunitinib in the first-line treatment of extensive-stage small cell lung cancer.
41. Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small cell lung cancer.
42. Clinical relevance of HER2 expression/activation, as measured in circulating tumor cells by a multiplexed immunoassay, in women with HER2-negative (by FISH) metastatic breast cancer (MBC).
43. Treatment of carcinoma of unknown primary site (CUP) directed by molecular profiling diagnosis: A prospective, phase II trial.
44. An open-label randomized phase II trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) compared to carboplatin and paclitaxel in patients with previously untreated carcinoma of unknown primary.
45. Phase II trial of radiation therapy/temozolomide/bevacizumab followed by bevacizumab/everolimus in the first-line treatment of glioblastoma multiforme (GBM).
46. BRIDGE: An open-label phase II trial evaluating the safety of bevacizumab (BV) plus paclitaxel/carboplatin (PC) as first-line treatment (tx) for patients (pts) with advanced, previously untreated, squamous non-small cell lung cancer (NSCLC).
47. A phase II trial of preoperative chemoradiation therapy plus bevacizumab and erlotinib in the treatment of localized esophageal cancer.
48. Phase II trial of radiation therapy/temozolomide followed by temozolomide/sorafenib in the first-line treatment of glioblastoma multiforme (GBM)
49. Preliminary safety results from a multicenter phase II trial of nanoparticle albumin-bound paclitaxel/cyclophosphamide in early stage breast cancer plus trastuzumab in HER-2+ patients (pts)
50. Combined modality therapy with radiation therapy (RT), chemotherapy, bevacizumab, and erlotinib in the treatment of patients (pts) with locally advanced squamous carcinoma of the head and neck
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.